HAYA Therapeutics to Present on RNA-Guided Regulatory Genome Platform at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
HAYA Therapeutics, SA, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics that reprogram disease-driving cell states for rare, common, chronic and age-related diseases, today announced the presentation of data at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) in New Orleans from May 13-17, 2025.
HAYA Therapeutics Awarded Innosuisse Certificate for Sustainable Growth and Funding to Advance Treatment for Aggressive Solid Tumors
HAYA Therapeutics, SA, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics for rare, common, chronic and age-associated diseases, announced that it has been awarded the prestigious Innosuisse Certificate for Sustainable Growth from Innosuisse, the Swiss Innovation Agency, who also provided funding to support HAYA’s research into using its technology to address cancer.
HAYA Therapeutics Announces Collaboration with Lilly to Discover Novel Regulatory Genome Targets for Obesity and Related Metabolic Conditions Using Proprietary RNA Platform
HAYA Therapeutics, SA, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics for chronic diseases, today announced a multi-year agreement with Eli Lilly and Company to apply HAYA’s advanced RNA-guided regulatory genome platform to support preclinical drug discovery efforts in obesity and related metabolic conditions. The partners will identify multiple regulatory genome derived RNA-based drug targets to address these chronic conditions.
HAYA Therapeutics Appoints Former Roche Global Head of Operations Eric Adam, Ph.D. as Chief Operating Officer
HAYA Therapeutics, SA, a company developing RNA-guided programmable precision medicines focused on long non-coding RNAs (lncRNAs), today announced that Eric Adam, Ph.D. has joined as Chief Operating Officer (COO). With over 25 years of experience in health technology and healthcare sectors, Eric joins HAYA’s team in Lausanne after serving as Global Head of Operations within Neuroscience and Rare Diseases in Pharma Research and Early Development (pRED) at Roche. As COO, Dr. Adam’s will help HAYA streamline operations to support scalable growth and international expansion, ensuring the company continues to lead in precision RNA-targeted therapeutics and supporting the development of strategic partnerships and product portfolio initiatives.
HAYA Therapeutics Adds Douglas L. Mann, M.D. as Chairperson of Clinical Advisory Board
HAYA Therapeutics, SA, a company developing RNA-guided programmable precision medicines focused on long non-coding RNAs, today announced that Douglas L. Mann, M.D. is joining as Chairperson of the company’s Clinical Advisory Board.
HAYA Therapeutics Adds World-Leading Cardiologist and Dark Genome Pioneer to Advisory Boards
HAYA Therapeutics, SA, a company developing RNA-guided programmable precision medicines focused on long non-coding RNAs (lncRNAs), today announced that Ahmad Masri, M.D., M.S. and Cedric Feschotte, Ph.D. are joining HAYA’s advisory boards.
HAYA Therapeutics Completes CHF 18 Million Seed Financing To Advance Anti-fibrotic Therapies Targeting Long Non-coding RNAs
HAYA Therapeutics, SA, a company developing precision medicines that target tissue and cell-specific long non-coding RNAs (lncRNAs), announced the successful closing of its CHF 18 million seed round. The financing was led by Broadview Ventures, with participation from Apollo Health Ventures, BERNINA BioInvest, 4See Ventures, Schroder Adveq and Viva BioInnovator.
